<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02335879</url>
  </required_header>
  <id_info>
    <org_study_id>GenSci 008 CT</org_study_id>
    <nct_id>NCT02335879</nct_id>
  </id_info>
  <brief_title>Phase III Clinical Study of Domestic Recombinant Human Follitropin for Injection to Treat WHO Class II Anovulation</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeneScience Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Reproductive &amp; Genetic Hospital of CITIC-Xiangya</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shengjing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GeneScience Pharmaceuticals Co., Ltd.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Domestic Recombinant&#xD;
      Human Follitropin (Gonal-F) for Injection for treatment of WHO Ⅱ anovulation (including&#xD;
      polycystic ovarian syndrome [PCOS] subjects).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The efficiency reached mature follicle (the diameter of follicular ≥18mm by type-B ultrasonic) within the start period on the day of HCG day.</measure>
    <time_frame>participants will be followed within the HCG day, an expected average of 14±2 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">534</enrollment>
  <condition>Anovulation</condition>
  <arm_group>
    <arm_group_label>Recombinant Human Follitropin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gonal-F</intervention_name>
    <arm_group_label>Recombinant Human Follitropin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Married infertile women at the age of 21-38.&#xD;
&#xD;
          -  BMI&lt;28kg/m2.&#xD;
&#xD;
          -  According to the detection level of serum estradiol (E2), prolactin (PRL),&#xD;
             progesterone (P), testosterone (T), luteinizing hormone (LH), follicle stimulating&#xD;
             hormone (FSH), subjects were diagnosed of WHO class II anovulation or oligo-ovulation,&#xD;
             and the above hormone level of the subject is normal or normal after treatment at the&#xD;
             beginning of study, and FSH&lt;10IU/L.&#xD;
&#xD;
          -  Bilateral fallopian tubes are unobstructed proved by hysterosalpingograph or&#xD;
             laparoscopic examination within one year, no history of abortion or pelvic infection&#xD;
             after the examination, the researcher decide whether the above examination need to&#xD;
             repeat. If the subject had salpingoplasty under laparoscope, and the bilateral&#xD;
             fallopian tubes are unobstructed after the surgery, there is no need to have the&#xD;
             hysterosalpingograph. If it can not be confirmed, it must be done again to prove that&#xD;
             the bilateral fallopian tubes are unobstructed.&#xD;
&#xD;
          -  Vaginal B-ultrasound examination shows that there is no ovarian pathological tumor, no&#xD;
             hysteromyoma or hysteromyoma&lt;4cm, and does not affect the endometrial function.&#xD;
&#xD;
          -  Two examinations of spouse semen are normal within six months, or comply with the IUI&#xD;
             standard.&#xD;
&#xD;
          -  No history of drug abuse.&#xD;
&#xD;
          -  Voluntarily sign the informed consent form and agree with medication and accepting&#xD;
             evaluation according to the requirements of the research protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject use gonadotropin therapy within the past three months (regardless the&#xD;
             result of treatment).&#xD;
&#xD;
          -  The uterine factors affect pregnancy and other tumors.&#xD;
&#xD;
          -  Pregnancy contraindication, such as genetic diseases, mental diseases, drug abuse,&#xD;
             sexually transmitted diseases, severe heart disease and hepatic and kidney function&#xD;
             insufficiency.&#xD;
&#xD;
          -  Obscure vaginal bleeding.&#xD;
&#xD;
          -  Subjects are allergic to the application of FSH/HMG and HCG in the past.&#xD;
&#xD;
          -  Other conditions that the researchers think they are not suitable for the clinical&#xD;
             trials.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>January 5, 2015</study_first_submitted>
  <study_first_submitted_qc>January 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2015</study_first_posted>
  <last_update_submitted>January 9, 2015</last_update_submitted>
  <last_update_submitted_qc>January 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anovulation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

